Sales of Johnson  Johnsons new hepatitis C drug soared during its first full quarter on the market in another sign of strong demandand high pricesfor a new generation of treatments for the liverdamaging illness The higherthanexpected  million in firstquarter sales for JJs Olysio follows evidence that another new hepatitis C drug Gilead Sciences Incs Sovaldi is having one of the bestselling drug launches ever Gilead is scheduled to release results next week some analysts believe Sovaldis firstquarter
  